Contrasting Beam Therapeutics (NASDAQ:BEAM) and PTC Therapeutics (NASDAQ:PTCT)

Beam Therapeutics (NASDAQ:BEAM) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Beam Therapeutics and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-73.04%	-32.76%	-25.80%
PTC Therapeutics	-9.17%	N/A	-0.10%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Beam Therapeutics and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1	2	9	1	2.77
PTC Therapeutics	1	3	10	1	2.73

Beam Therapeutics presently has a consensus price target of $47.64, indicating a potential upside of 98.24%. PTC Therapeutics has a consensus price target of $99.23, indicating a potential upside of 56.61%. Given Beam Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than PTC Therapeutics.

Volatility & Risk

Beam Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Earnings & Valuation

This table compares Beam Therapeutics and PTC Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74 million	17.80	-$79.99 million	($1.04)	-23.11
PTC Therapeutics	$1.16 billion	4.58	$682.64 million	($1.40)	-45.26

PTC Therapeutics has higher revenue and earnings than Beam Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

PTC Therapeutics beats Beam Therapeutics on 7 of the 13 factors compared between the two stocks.

About Beam Therapeutics

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.

About PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.